A recently presented concept of Alzheimer disease (AD) is based on a primarily ischemic (rather than degenerative) type of brain disease. Etiologically, this new concept is presumed to be related to the human upright gait along with individual predisposition.
The proposed treatment—head-down therapy (HDT)—is the centerpoint of this presentation: a simple and generally accessible type of therapy, with monitoring by neuropsychological questioning, electroencephalography, and transcranial Doppler. As a treatment of AD (limited to stage 1), HDT is expected to be helpful. It is possible, however, that its prophylactic use may be of even greater importance.
NiedermeyerE.Alzheimer disease: Caused by primary deficiency of the cerebral blood flow. Clin EEG Neurosci2006;37:175–177.
2.
PogarellOMulertCHegerU.Event-related potentials and fMRI in neuropsychopharmacology. Clin EEG Neurosci2006;37:99–107.
3.
SilvestriniMPasqualettiPBaruffaldiRBartoliniMHandoukYMatteisMMoffaFProvincialiLVernieriF.Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke2006;37:1010–1015.
4.
RuitenbergAden HeuerTBakkerSLMVan SwietenJCKoudstallPJHofmanABretelerMMBCerebral hypoperfusion and clinical onset of dementia: The Rotterdam Study. Ann Neurol2005;57:789–794.
